Vanguard Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.34B | Buy |
|
|||||
|
2025
Q1 | $3.53B | Buy |
|
|||||
|
2024
Q4 | $3B | Buy |
|
|||||
|
2024
Q3 | $3.48B | Buy |
|
|||||
|
2024
Q2 | $3.04B | Buy |
|
|||||
|
2024
Q1 | $1.79B | Buy |
|
|||||
|
2023
Q4 | $2.29B | Buy |
|
|||||
|
2023
Q3 | $2.06B | Buy |
|
|||||
|
2023
Q2 | $2.21B | Buy |
|
|||||
|
2023
Q1 | $2.33B | Buy |
|
|||||
|
2022
Q4 | $2.73B | Buy |
|
|||||
|
2022
Q3 | $2.21B | Buy |
|
|||||
|
2022
Q2 | $1.61B | Buy |
|
|||||
|
2022
Q1 | $1.77B | Buy |
|
|||||
|
2021
Q4 | $1.81B | Buy |
|
|||||
|
2021
Q3 | $2B | Buy |
|
|||||
|
2021
Q2 | $1.78B | Sell |
|
|||||
|
2021
Q1 | $1.49B | Buy |
|
|||||
|
2020
Q4 | $1.37B | Sell |
|
|||||
|
2020
Q3 | $1.53B | Sell |
|
|||||
|
2020
Q2 | $1.61B | Buy |
|
|||||
|
2020
Q1 | $1.15B | Buy |
|
|||||
|
2019
Q4 | $1.18B | Buy |
|
|||||
|
2019
Q3 | $817M | Buy |
|
|||||
|
2019
Q2 | $676M | Buy |
|
|||||
|
2019
Q1 | $809M | Buy |
|
|||||
|
2018
Q4 | $599M | Buy |
|
|||||
|
2018
Q3 | $666M | Buy |
|
|||||
|
2018
Q2 | $742M | Buy |
|
|||||
|
2018
Q1 | $887M | Buy |
|
|||||
|
2017
Q4 | $923M | Buy |
|
|||||
|
2017
Q3 | $763M | Buy |
|
|||||
|
2017
Q2 | $512M | Buy |
|
|||||
|
2017
Q1 | $290M | Buy |
|
|||||
|
2016
Q4 | $204M | Buy |
|
|||||
|
2016
Q3 | $367M | Buy |
|
|||||
|
2016
Q2 | $299M | Buy |
|
|||||
|
2016
Q1 | $327M | Buy |
|
|||||
|
2015
Q4 | $475M | Buy |
|
|||||
|
2015
Q3 | $372M | Buy |
|
|||||
|
2015
Q2 | $544M | Buy |
|
|||||
|
2015
Q1 | $452M | Buy |
|
|||||
|
2014
Q4 | $361M | Buy |
|
|||||
|
2014
Q3 | $280M | Buy |
|
|||||
|
2014
Q2 | $207M | Buy |
|
|||||
|
2014
Q1 | $180M | Sell |
|
|||||
|
2013
Q4 | $191M | Buy |
|
|||||
|
2013
Q3 | $182M | Buy |
|
|||||
|
2013
Q2 | $84.8M | Buy |
|